Prof. Dr. med. Dr. med. habil. Sigmund Silber
FESC, FACC, FAHA
Kardiologe

CURRICULUM VITAE

Sigmund Silber, MD, PhD
Professor of Medicine
FESC, FACC, FAHA
Cardiologist

sigmund@silber.com
www.sigmund-silber.com
Cardiology Practice and Heart Center at the Isar, Munich, Germany

Participation in Clinical Multicenter Studies

A.A.C.H.E.N. (Angiotensin-II Antagonist to reduce post Coronary stent Hyperplasia of Endothelial Neointima)


ACUITY (A randomized comparison of bivalirudin vs. heparin and GP IIb/IIIa inhibitors in patients undergoing early invasive management for NSTE-ACS)



BETA-CATH (Beta Cath System Study for brachytherapy of de-novo coronary lesions)


BRIE (Beta Radiation In Europe), Principal Investigator for Germany


CAST (Cardiac Arrythmia Supression Trial)


CHARISMA (Clopidogrel for High Atherothrombotic Risk and Ischaemic Stabilization)


CYPHER (German Registry for prospective Evaluation and Follow-up of Patients after Cypher Stent Implantation)


DaVINCI (Registry for prospective Evaluation and Follow-up of Patients after Vision Stent Implantation)


DES.DE (German Drug-Eluting Stent Registry), Member of the Steering Committee


DETECT (Diabetes Cardiovaskular Risk-Evaluation), Member of the Steering Committee


DUETT (A Novel Vascular Sealing Device for Closure of Percutaneous Arterial Access Sites), Principal Investigator


EBEAT (Electron Beam Computed Tomography assessment of coronary calcification), Member of the Safety/Endpoint Committee (SEC)


ENDEAVOR II (Randomized, controlled trial to Evaluate the AVE ABT-578 Eluting Driver Sten)



EUROSTAR II (European prospective study of the COSTAR Paclitaxel-Eluting Coronary Stent System as compared to the bare stent), Principal Investigator


EVIDENT (Endovascular Investigation Determining the safety of new Tacrolimus-eluting stent grafts)


EVOLVE-II (Randomized Evaluation of a Novel Bioabsorbable Polymer-Coated, Everolimus-Eluting Coronary Stent), Principal National Investigator



HEALING II + IIb (Healthy Endothelial Accelerated Lining Inhibits Neointimal Growth: Progenitor Endothelial Cells)



ISAR-PROJECT-2 (Clinical Evaluation of on-site coating with two Rapamycin dose regimes)


IST (Intracoronary Radiation Therapy), Principal Investigator


IT Biodegradable Study (The Biodegradable Poly-L-Lactic Acid Igaki-Tamai Coronary Stent), Principal Investigator


LUNAR ROX (Registry for prospective Evaluation of Patients after Lunar Rox Stent Implantation), Principal Investigator


LUSTY (Lunar Stent study), Principal Investigator


MASTER (The MGuard mesh-based Embolic Protection Stent for Acute ST-Elevation Reperfusion Trial), Co-Principal Investigator


MUNICH (Multislice Normal Incidence of Coronary Health), Principal Investigator


NOBORI-1 (Prospective, Randomized, Multi-Center Comparison of the Nobori and Taxus Drug Eluting Stent System), Member of the Steering Committee


NIRTOP ('Fused-Gold' vs. 'Bare' Stainless Steel NIRflex Stents), Member of the Steering Committee



OPEN II (Assessment of the STENTYS Paclitaxel-eluting selfexpanding stent in coronary bifurcation lesions)



PLATINUM PLUS (Randomized Multicenter Trial to Assess the Everolimus-Eluting Coronary Stent System), Co-Principal Investigator


RECALL (Heinz Nixdorf Recall Study), Advisory Board


REMEDEE (Randomized Study to Evaluate the Combo Abluminal Sirolimus Coated Bio-Engineered Stent)




RESOLUTE-AC (All-Comers Randomized Comparison of a Zotarolimus-Eluting Stent with an Everolimus-Eluting Stent for PCI), Co-Principal Investigator


REVEAL HPS 3 / TIMI 55 (Randomized Evaluation of Anacetrapib in pats. with established vascular disease for increasing HDL-Cholesterol)


SAFE (A global post-market surveillance for the Dexamethason eluting Stent)







TAXUS-VI (Randomized, double-blind study to assess paclitaxel-eluting stents in the treatment of longer lesions)


OLYMPIA (Global TAXUS Liberté Registry)


ZOMAXX I (Randomized Evaluation of the Zomaxx ABT 578-eluting stent compared to the Taxus Express Paclitaxel-Eluting Stent)